Thursday, February 4, 2016, 9:00 a.m. EST
Increasing the level of a naturally-produced protein, called tristetraprolin (TTP), significantly reduced or protected mice from inflammation, according to researchers at the National Institutes of Health. The results suggest that pharmaceutical compounds or other therapeutic methods that produce elevated levels of TTP in humans may offer an effective treatment for some inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis. The report appeared online Feb. 1 in the Proceedings of the National Academy of Sciences.
Inflammation has been proven to play a major role in a number of normal processes in humans, but it also fosters diseases, many of which are increasing in prevalence and severity. The development of new therapies for treating inflammatory diseases could greatly reduce the growing health burden.
With this goal in mind, Perry Blackshear, M.D., D.Phil., a researcher at the National Institute of Environmental Health Sciences (NIEHS), part of NIH, led the team that genetically altered the TTP gene in mice, so that the animals produced higher than normal amounts of the TTP protein. The mice were then tested using experimental models of rheumatoid arthritis, psoriasis, and multiple sclerosis. Experimental models are used to study processes thought to be involved in human diseases, and to evaluate and select therapies that affect these processes.
"Mice with more TTP in their bodies were resistant to the inflammation that accompanied these experimental models of disease," Blackshear said. "We also found evidence of how TTP is providing this protection."
Blackshear said TTP exerts its beneficial effect by targeting several messenger molecules that encode cytokines, proteins known to be involved in inflammation. TTP binds to these molecules and destabilizes them, resulting in lower levels of cytokines and, thus, decreased inflammation.
Blackshear anticipates that TTP-based treatments would be cost effective and easy to administer. Future work will seek to identify compounds that have similar effects on the levels of TTP in the body.
"Many current therapies for these inflammatory diseases are expensive and require the medicines be introduced into the body under the skin, in the muscle, or by intravenous injection," said Sonika Patial, D.V.M., Ph.D., a research fellow in Blackshear’s research group and lead author on the paper. "Our ideal treatments would be administered orally in pill or liquid form."
Patial S, Curtis II AD, Lai WS, Stumpo DJ, Hill GD, Flake GP, Mannie MD, Blackshear PJ. 2016. Enhanced stability of tristetrapolin mRNA protects mice against immune-mediated inflammatory pathologies. Proc Natl Acad Sci U S A; doi:10.1073/pnas.1519906113 [Online 1 February 2016].
NIEHS supports research to understand the effects of the environment on human health and is part of NIH. For more information on environmental health topics, visit http://www.niehs.nih.gov. Subscribe to one or more of the NIEHS news lists (NIEHS Newsroom Releases) to stay current on NIEHS news, press releases, grant opportunities, training, events, and publications.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health®